Table 2.
Laboratory characteristics, treatment, and outcomes of patients
| Laboratory Characteristics | |
|---|---|
| SARS-Cov-2 Antibody Positivity (n/%) | 52/77.6 |
| Both Serologic And RT-PCR Test Positivity (n/%) | 9/13.4 |
| With Contact History (n/%) | 6/18 |
| White Blood Cell Count * | 10,040 (7080–14,780) |
| Lymphocyte * | 1390 (870–2260) |
| Neutrophile Lymphocyte Ratio | 5.3 (2.4–11) |
| C Reactive Protein (mg/dL) * | 13.2 (17.9–20.4) |
| Ferritin (ng/mL)* | 340.7 (201–671) |
| Troponine (ng/mL)* | 0.005 (0.003–0.044) |
| IL-6 level (pg/ml)* | 45. 5 (11.7–197.5) |
| Brain Natriuretic Peptide (pg/mL)* | 228 (87.5–1296) |
| D-Dimer (mg/mL FEU)* | 2380 (1255–4127) |
| Treatments | |
| Corticosteroids (n/%) | 45/67 |
| Intravenous Immunoglobulin (n/%) | 58/85 |
| Anakinra (n/%) | 17/25.3 |
| Treatment Duration of Anakinra * | 8 (6.5–13) |
| Tocilizumab (n/%) | 1/1.5 |
| Vasoactive Medications (n/%) | 14/21 |
| Enoxaparin (n/%) | 42/63 |
| Outcomes | |
| Duration of Hospitalization (days)# | 11.8 ± 7.07 |
| Admission of PICU (n/%) | 21/31.3 |
| Duration of PICU (median (IQR)) | 4.7 (4–8) |
| Utilization of mechanical ventilator (n/%) | 2/3 |
| Utilization of ECMO (n/%) | 2/3 |
| Mortality (n/%) | 2/3 |
*(median (IQR)) # mean±SD, IQR: Interquartile range, PICU: Pediatric Intensive Care Unit, ECMO: Extracorporeal Membrane Oxygenation